Redefining drug targeting to maximize success in clinical trials
MEDiC supports preclinical cancer drugs survive in the clinical trials, where traditionally only about 10% of drug pass the trials and survive.
High failure = Expensive drug
93.3 %
Failure rate of oncology drugs at Phase I (2004-2011)
3 Major Failure Reasons
Lack of Biomarkers
Hidden resistance mechanisms
Lack of Target validation
MEDIC’s Solution
MEDiC provides a new approach to identify biomarkers and mechanisms of resistance for oncology drugs before they enter the clinic
Science
Genome-scale CRISPR/Cas9 functional genomics tool imbedded in hundreds of cancer organoids per cancer type
3D cancer organoids, more accurately recapitulate tumors in human body
Our preclinical model tests the effect of millions of genetic variations on the response to a drug
Contact
MEDIC Life Sciences
930 Brittan Ave, San Carlos, CA 94070, USA
Send Us a Message
Copyright MEDIC Life Sciences – All rights reserved
